Combination chemotherapy of docetaxel and cisplatin in treatment of advanced non-small-cell lung cancer

Objective: To investigate the therapeutic efficacy and toxicity of combination chemotherapy of weekly docetaxel and cisplatin in treatment of advanced non-small-cell lung cancer(NSCLC).Methods: All the patients received the following regimen:docetaxel 20-30 mg/m²(median dose 24.5 mg/m² per week) intravenous infusion per week for 6 weeks,cisplatin 25 mg/m² intravenous infusion on day 1,2,3 and on day 22,23,24 before docetaxel infusion.The patients were premedicated with dexamethasone 8 mg twice for 3 days.All the patients received chemotherapy for more than 8 weeks.Results: The effect was assessed in 34 cases.Among them,PR was found in 14 cases(41.2%),SD in 16 cases and PD in 4 cases.The overall response rate was 41.2%.The median survival time was 11.6 months and 1 year survival rate was 48%.The main toxicity profile was myelosuppression,diarrhea,muscle pain,nausea/vomiting,heptic function damage and rash.Most adverse effects were classified as grade 1 or grade 2.No allergic reaction or liqual retention was observed after preservation.Conclusions: The combination chemotherapy of weekly docetaxel and cisplatin is effective for treatment of advanced NSCLC with slight toxicity reactions.